Regulation of articular chondrocyte aggrecan and collagen gene expression by multiple growth factor gene transfer

被引:38
作者
Shi, Shuiliang [1 ]
Mercer, Scott [1 ]
Eckert, George J. [2 ]
Trippel, Stephen B. [1 ,3 ]
机构
[1] Indiana Univ Sch Med, Dept Orthopaed Surg, Indianapolis, IN USA
[2] Indiana Univ Sch Med, Dept Med, Div Biostat, Indianapolis, IN USA
[3] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN USA
关键词
growth factors; aggrecan; collagen; articular chondrocytes; gene therapy; DEFECTS IN-VIVO; IGF-I; CARTILAGE EXPLANTS; MATRIX SYNTHESIS; ALGINATE BEADS; FACTOR-BETA; REPAIR; OVEREXPRESSION; PROTEOGLYCANS; METABOLISM;
D O I
10.1002/jor.22036
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Gene transfer is a promising approach to the delivery of chondrotrophic growth factors to promote cartilage repair. It is unlikely that a single growth factor transgene will optimally regulate these cells. The aim of this study was to identify those growth factor transgene combinations that optimally regulate aggrecan, collagen type II and collagen type I gene expression by articular chondrocytes. We delivered combinations of the transgenes encoding fibroblast growth factor-2, insulin-like growth factor I, transforming growth factor beta1, bone morphogenetic protein-2, and/or bone morphogenetic protein-7 and assessed chondrocyte responses by measuring changes in the expression of aggrecan, type II collagen and type I collagen genes. These growth factor transgenes differentially regulated the magnitude and time course of all three-matrix protein genes. In concert, the transgenes regulated matrix gene expression in an interactive fashion that ranged from synergistic to inhibitory. Maximum stimulation of aggrecan (16-fold) and type II collagen (35-fold) expression was with the combination of IGF-I, BMP-2, and BMP-7 transgenes. The results indicate that the optimal choice of growth factor genes for cell-based cartilage repair cannot be predicted from observations of individual transgenes. Rather, such gene therapy will require an empirically based selection of growth factor gene combinations. 2011 Orthopaedic Research Society. This article is a US Government work and as such is in the public domain in the United States of America. Published by Wiley Periodicals, Inc. J Orthop Res 30:10261031, 2012
引用
收藏
页码:1026 / 1031
页数:6
相关论文
共 38 条
  • [31] Smith P, 2000, ARTHRITIS RHEUM-US, V43, P1156, DOI 10.1002/1529-0131(200005)43:5<1156::AID-ANR26>3.0.CO
  • [32] 2-M
  • [33] Szebenyi G, 1999, INT REV CYTOL, V185, P45
  • [34] Controlling cell fate by bone morphogenetic protein receptors
    ten Dijke, P
    Korchynskyi, O
    Valdimarsdottir, G
    Goumans, MJ
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2003, 211 (1-2) : 105 - 113
  • [35] Growth factors as therapeutic agents
    Trippel, SB
    Coutts, RD
    Einhorn, TA
    Mundy, GR
    Rosenfeld, RG
    [J]. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1996, 78A (08) : 1272 - 1286
  • [36] TRIPPEL SB, 1995, J RHEUMATOL, V22, P129
  • [37] The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models
    Yakar, S
    LeRoith, D
    Brodt, P
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2005, 16 (4-5) : 407 - 420
  • [38] Repair of articular cartilage defect by autologous transplantation of basic fibroblast growth factor gene-transduced chondrocytes with adeno-associated virus vector
    Yokoo, N
    Saito, T
    Uesugi, M
    Kobayashi, N
    Xin, KQ
    Okuda, K
    Mizukami, H
    Ozawa, K
    Koshino, T
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (01): : 164 - 170